Ovarian cancer is defined as a condition of abnormal ovarian cells growth of ovaries. It is one of most common cancer in US, according to the statistics adapted from the American Cancer Society's publication, Cancer Facts & Figures 2010, an estimated 21,880 women in the United States will be diagnosed with ovarian cancer and 13,850 deaths.
Phyllanthus niruri L.
Phyllanthus niruri L., also known as stonebreaker or seed-under-leaf, is a widespread tropical plant the genus Phyllanthus, belonging to the family Phyllanthaceae, native to to China, India and South/Central America. The herb has been used in folk medicine to treat kidney stones and in Indian medicine which is for problems of the stomach, genitourinary system, liver, kidney and spleen(32).
Corilagin, a major chemical constituent from Phyllanthus niruri L., inhibited the growth of the ovarian cancer cell lines SKOv3ip and Hey associated with cell cycle arrest at the G2/M stage and enhanced apoptosis(33). Other researchers suggested that Corilagin inhibited into the culture supernatant of all tested ovarian cancer cell lines through blocking the secretion of TGF-β(involved in many cellular processes)(34).
Chinese Secrets to Fatty Liver and Obesity Reversal
A fabulous E book with Research based & Scientifically proven Efficacy To Treat Fatty Liver Diseases & Achieve Optimal Health & Loose Weight
Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months
Super foods Library, Eat Yourself Healthy With The Best of the Best Nature Has to Offer
Back to my Home page at http://thetruestoriesstories.blogspot.ca/
References
(32) "Keelanelli". Tamilnadu.com. 21 January 2013.
(33) A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways by Jia L1, Jin H, Zhou J, Chen L, Lu Y, Ming Y, Yu Y.(PubMed)
(34) A potential anti-tumor herbal medicine, Corilagin, inhibits ovarian cancer cell growth through blocking the TGF-β signaling pathways by Jia L1, Jin H, Zhou J, Chen L, Lu Y, Ming Y, Yu Y.(PubMed)
No comments:
Post a Comment